A Role for Virtual Biotechnology Companies in Drug Discovery and Development?

AbstrACt The orthodox business model of many drug discovery and development companies centres on adding value to early-stage discoveries prior to engaging with large pharmaceutical companies to bring products to market. Anecdotal observations suggest some companies are moving to a ‘virtual’ business model — instead of employing in-house scientists, a skeletal management team runs the company and out-sources all research and development. This article presents a novel method to determine whether companies are virtual, based on author bylines in peer-reviewed journal articles.Applying this method to Australian companies in this sector, the size of the cohort identified as virtual was much larger than anticipated, around 52%. The accuracy of this method has been verified statistically using interview data. This article discusses the value and limitations of this method, positing that it can be used to analyse industry and policy implications that may result from widespread adoption of the virtual model

[1]  D. Kamuriwo.  TIMING IN BUSINESS MODEL AND PRODUCT MARKET STRATEGY TRADEOFFS: PERFORMANCE IMPLICATIONS. , 2009 .

[2]  R. Dellavalle,et al.  The write position , 2007, EMBO reports.

[3]  David J. Teece,et al.  The Market for Know-How and the Efficient International Transfer of Technology , 1981 .

[4]  Benjamin Coriat,et al.  Does Biotech Reflect a New Science-based Innovation Regime? , 2003 .

[5]  David L. Deeds,et al.  Exploration and Exploitation Alliances in Biotechnology: A System of New Product Development , 2004 .

[6]  G D Lundberg,et al.  The order of authorship: who's on first? , 1990, JAMA.

[7]  D. Teece,et al.  Organizing for innovation: When is virtual virtuous? , 2002 .

[8]  Bruce Rasmussen.  Innovation and Commercialisation in the Biopharmaceutical Industry: Creating and Capturing Value , 2010 .

[9]  S. Aldridge.  Biotechs go virtual , 2010, Nature Biotechnology.

[10]  J. Chakma,et al.  Is it virtuous to be virtual? The VC viewpoint , 2009, Nature Biotechnology.

[11]  Ashish Arora,et al.  A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development , 2009, Manag. Sci..

[12]  W. Edward Steinmueller.  The Role of Technical Standards in Coordinating the Division of Labour in Complex System Industries , 2003 .

[13]  Philip Mirowski,et al.  The Contract Research Organization and the Commercialization of Scientific Research , 2005, Social studies of science.

[14]  H. Chesbrough,et al.  The Role of the Business Model in Capturing Value from Innovation: Evidence from Xerox Corporation's Technology Spin-Off Companies , 2002 .

[15]  Gary P. Pisano,et al.  Science Business: The Promise, the Reality, and the Future of Biotech , 2006 .